U.S. Asthma and COPD Drugs Market Value Share Analysis, by Indication, 2016 and 2024
The market for asthma and COPD drugs in the U.S. and China is poised to present a steady incremental opportunity in the years to come. A rise in the affected patient pool, an improved diagnosis rate for respiratory diseases, and heightened patient awareness regarding treatment options are identified as the key factors driving this market.
View full press release